公开(公告)号：US20230372361A1

公开(公告)日：2023-11-23

申请号：US18008605

申请日：2021-06-25

申请人： Durect Corporation ,  Virginia Commonwealth University ,  The United States Government as Represented by the Department of Veterans Affairs

发明人： Shunlin Ren ,  Yaping Wang ,  WeiQi Lin ,  James E. Brown ,  Felix Theeuwes

IPC分类号： A61K31/575 ,  A61P29/00

CPC分类号： A61K31/575 ,  A61P29/00

摘要： Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia. In some cases, the at least one inflammatory condition is associated with Epstein-Ban virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

公开(公告)号：US20230310458A1

公开(公告)日：2023-10-05

申请号：US18115286

申请日：2023-02-28

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  Felix Theeuwes ,  James E. Brown ,  WeiQi Lin

IPC分类号： A61K31/575 ,  A61K31/568 ,  A61P13/12 ,  A01N1/02 ,  A61K35/12

CPC分类号： A61K31/575 ,  A61K31/568 ,  A61P13/12 ,  A01N1/0226 ,  A61K35/12

摘要： Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

公开(公告)号：US20210169902A1

公开(公告)日：2021-06-10

申请号：US17072994

申请日：2020-10-16

申请人： Virginia Commonwealth University ,  Durect Corporation

发明人： Shunlin Ren ,  WeiQi Lin ,  James E. Brown ,  Felix Theeuwes ,  Mee Jean Kim ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee ,  Huey-Ching Su ,  Wilma Tamraz

IPC分类号： A61K31/575 ,  A61P17/06 ,  A61K9/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14

摘要： Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10272097B2

公开(公告)日：2019-04-30

申请号：US15106883

申请日：2014-12-23

申请人： VIRGINIA COMMONWEALTH UNIVERSITY ,  DURECT CORPORATION

发明人： Shunlin Ren ,  Felix Theeuwes ,  James E. Brown ,  WeiQi Lin

IPC分类号： A61K31/56 ,  A61K31/575 ,  A61K31/568 ,  A01N1/02 ,  A61K35/12

摘要： Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

公开(公告)号：US20190070206A1

公开(公告)日：2019-03-07

申请号：US16053736

申请日：2018-08-02

申请人： Durect Corporation

发明人： Michael Sekar ,  Su Il Yum ,  Felix Theeuwes ,  William Van Osdol

IPC分类号： A61K31/7052 ,  A61K41/00 ,  A61K47/52 ,  A61K9/16 ,  A61L2/00 ,  A61K9/00 ,  A61K9/19 ,  C07K14/575 ,  A61K38/22 ,  A61K38/17 ,  C07K14/61 ,  A61K31/198 ,  A61K45/06 ,  A61K38/27 ,  A61K38/26 ,  A61K47/64

摘要： The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided.

公开(公告)号：US20220257619A1

公开(公告)日：2022-08-18

申请号：US17627000

申请日：2020-07-17

申请人： Gilead Sciences, Inc. ,  Durect Corporation

发明人： Susan Autio ,  Keith Edward Branham ,  James A. Filice ,  John W. Gibson ,  John J. Leonard ,  James Matriano ,  Whitney Moro ,  Michael Sekar ,  Chelsea Alexandra Snyder ,  Robert G. Strickley ,  Raju Subramanian ,  Felix Theeuwes ,  Monica Tijerina ,  Jeremy C. Wright ,  Su Il Yum ,  Faye Xu

IPC分类号： A61K31/675 ,  A61K47/26 ,  A61K47/34 ,  A61K47/22 ,  A61P31/18

摘要： The present disclosure provides long-acting formulations of tenofovir alafenamide, methods of making the same and methods of using the same.

公开(公告)号：US20170189547A1

公开(公告)日：2017-07-06

申请号：US15356488

申请日：2016-11-18

申请人： Durect Corporation

发明人： William W. van Osdol ,  Su Il Yum ,  Felix Theeuwes ,  Michael Sekar ,  John W. Gibson ,  Keith E. Branham ,  Huey-Ching Su

IPC分类号： A61K48/00 ,  A61K47/14 ,  A61K47/10 ,  A61K9/00 ,  A61K38/27 ,  A61K38/21 ,  A61K31/7052 ,  A61K38/26 ,  A61K47/26 ,  A61K47/34 ,  A61K47/48

CPC分类号： A61K38/212 ,  A61K9/0019 ,  A61K31/7052 ,  A61K38/26 ,  A61K38/27 ,  A61K47/14 ,  A61K47/26 ,  A61K47/34 ,  A61K47/52 ,  A61K47/541 ,  A61K47/64

摘要： The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.

公开(公告)号：US11529420B2

公开(公告)日：2022-12-20

申请号：US16935110

申请日：2020-07-21

申请人： Durect Corporation

发明人： Michael Sekar ,  Felix Theeuwes ,  Keith Edward Branham ,  John W Gibson ,  James Matriano ,  Whitney Moro ,  John Tipton ,  William Van Osdol ,  Su Il Yum

IPC分类号： A61K31/352 ,  A61K31/706 ,  A61K31/785 ,  A61K38/26 ,  A61K38/27 ,  A61K47/54 ,  A61K9/16 ,  A61K9/19 ,  A61K9/00 ,  A61K47/59 ,  A61K38/28 ,  A61K38/31 ,  A61K39/395

摘要： The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.

公开(公告)号：US20210322517A1

公开(公告)日：2021-10-21

申请号：US17222703

申请日：2021-04-05

申请人： DURECT CORPORATION

发明人： William Van Osdol ,  Su Il Yum ,  Felix Theeuwes ,  Michael Sekar ,  John W Gibson ,  Keith Edward Branham ,  Huey-Ching L. Su

IPC分类号： A61K38/21 ,  A61K47/54 ,  A61K47/52 ,  A61K47/64 ,  A61K47/14 ,  A61K47/26 ,  A61K47/34 ,  A61K9/00 ,  A61K31/7052 ,  A61K38/26 ,  A61K38/27

摘要： The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. In some cases, the composition includes sucrose acetate isobutyrate, biodegradable polymer, hydrophobic solvent, and a complex comprising a counterion and beneficial agent, such as protein, peptide, nucleic acid, or small molecular weight compound. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.

公开(公告)号：US20210038731A1

公开(公告)日：2021-02-11

申请号：US16935110

申请日：2020-07-21

申请人： Durect Corporation

发明人： Michael Sekar ,  Felix Theeuwes ,  Keith Edward Branham ,  John W. Gibson ,  James Matriano ,  Whitney Moro ,  John Tipton ,  William Van Osdol ,  Su Il Yum

IPC分类号： A61K47/54 ,  A61K9/16 ,  A61K9/19 ,  A61K9/00 ,  A61K47/59 ,  A61K38/26 ,  A61K31/352 ,  A61K31/706 ,  A61K31/785 ,  A61K38/27 ,  A61K38/28 ,  A61K38/31 ,  A61K39/395

摘要： The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.